Parocin; reumoxicam; Movicox; Mobic; Mobicox; Movalis; Meloxicamum; Uticox;
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
化合物 5,美洛昔康,是一种抑制 COX 活性的非甾体类抗炎药。 COX-2 和 COX-1 的 IC50 值分别为 0.49 µM 和 36.6 µM[1]。在 0.25–25 µg/mL 浓度下,美洛昔康对 MDCK 或 CF41.Mg 肿瘤细胞不表现出任何细胞毒性,但会抑制 COX+ 肿瘤细胞。此外,阿霉素和美洛昔康对 CF41.Mg 细胞没有协同作用。 Meloxicam (0.25 µg/mL) 抑制 CF41.Mg 细胞的迁移和侵袭,减少 MMP-2 的产生,并增加 CF41.Mg 细胞中 β-catenin 的磷酸化;然而,它对CF41.Mg细胞的凋亡没有影响[2]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
在小鼠中,与福尔马林治疗组相比,单独使用美洛昔康(10 mg/kg)或与芦丁联合使用的第一天小鼠喜欢爪子的时间分别显着缩短了 55% 和 49%;然而,该组合并没有显着减少第三天的时间。此外,美洛昔康单独使用或与芦丁联合使用可降低小鼠MDA含量,激活肝脏SOD活性,降低相对肝脏重量,抑制IL-1β含量,并显着降低小鼠体内caspase-3免疫反应阳性细胞的数量[3]。
|
||
动物实验 |
|
||
参考文献 |
[1]. Lazer ES, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997 Mar 14;40(6):980-9.
[2]. Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. [3]. Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32(2) |
分子式 |
C14H13N3O4S2
|
|
---|---|---|
分子量 |
351.4
|
|
精确质量 |
351.034
|
|
CAS号 |
71125-38-7
|
|
相关CAS号 |
Meloxicam-d3;942047-63-4;Meloxicam-d3-1;1227358-55-5;Meloxicam sodium;71125-39-8;Meloxicam-13C,d3;1309936-00-2
|
|
外观&性状 |
Solid powder
|
|
密度 |
1.6±0.1 g/cm3
|
|
沸点 |
581.3±60.0 °C at 760 mmHg
|
|
熔点 |
255ºC
|
|
闪点 |
305.4±32.9 °C
|
|
蒸汽压 |
0.0±1.7 mmHg at 25°C
|
|
折射率 |
1.735
|
|
LogP |
3.35
|
|
tPSA |
136.22
|
|
InChi Key |
DWMREKMVXIFPFM-ACCUITESSA-N
|
|
InChi Code |
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
|
|
化学名 |
(E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
|
|||
---|---|---|---|---|
溶解度 (体外实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (7.11 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL 澄清 DMSO 储备液加入900 μL 玉米油中,混合均匀。 配方 2 中的溶解度: ≥ 1 mg/mL (2.85 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 10.0 mg/mL澄清DMSO储备液加入400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL | |
5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL | |
10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05702827 | Recruiting | Drug: Bupivacaine-Meloxicam | Stress Urinary Incontinence Surgical Incision |
TriHealth Inc. | January 23, 2023 | Phase 3 |
NCT01161147 | Completed | Drug: Meloxicam | Healthy | Dr. Reddy's Laboratories Limited | October 2004 | Phase 1 |
NCT01161134 | Completed | Drug: Meloxicam | Healthy | Dr. Reddy's Laboratories Limited | September 2004 | Phase 1 |
NCT01801735 | Completed Has Results | Drug: Meloxicam Test Capsules | Osteoarthritis | Iroko Pharmaceuticals, LLC | March 2013 | Phase 3 |
Expression of COX-2 in MDCK and CF41.Mg cells. (A) Representative immunofluorescence images of the (left panel) negative control, where the nuclei were visualized by DAPI, and COX-2 expression in MDCK and CF41.Mg cells respectively (central and right panel). Scale bar, 32 µm. (B) Representative Western blot of the expression of COX-2 in cell lysates, demonstrating a band at 72 kDa in both cell lines. Results are representative of 3 independent experiments. COX, cycloooxgenase; MDCK, Madin-Darby Canine Kidney. td> |
Cell viability following incubation with different concentrations of meloxicam and/or doxorubicin. (A) CF41.Mg and (B) MDCK cells were incubated for 24 and 48 h with meloxicam (0–25 µg/ml). The percentage of viable cells was determined by MTS assay. Control cells were treated with DMSO alone. (C) Viability of CF41.Mg cells incubated for 24 and 48 h with meloxicam (0–25 µg/ml) and 500 ng/ml doxorubicin. (D) CF41.Mg cells were incubated with meloxicam (0–1 µg/ml) and 24 h later 500 ng/ml doxorubicin was added. Cell viability was measured at 24 and 48 h. Values are presented as the mean ± standard deviation of ≥3 independent experiments performed in triplicate. *P<0.05. td> |
Meloxicam (0.25 µg/ml) has no effect on CF41.Mg cell apoptosis. Doxorubicin alone (500 ng/ml) was used as a positive control. A total of 3 independent experiments were performed and values are presented as the mean ± standard deviation. Flow cytometry plots and analysis of the data are illustrated. *P<0.05 vs. the control group. td> |